📋 Key Information Summary
- Splenomegaly is defined as splenic enlargement beyond its normal weight of approximately 150g or length >12 cm on imaging.
- Systematic classification is essential: haematological malignancies, portal hypertension, infections, and storage disorders are the four major aetiological categories.
- Clinical examination for splenomegaly has moderate sensitivity; ultrasound is the first-line imaging modality for confirmation and measurement.
- Initial investigation requires a complete blood count, peripheral blood film, and liver function tests to narrow the differential.
- Massive splenomegaly (splenic weight >1000g or extending to the iliac crest) is highly suggestive of myeloproliferative neoplasms or chronic lymphocytic leukaemia.
- Management is directed at the underlying cause; splenectomy is considered for symptomatic hypersplenism, diagnostic uncertainty, or specific haematological disorders.
- All patients with splenomegaly require assessment for hypersplenism (cytopenias) and risk of splenic rupture.
- Key investigations include FBC, blood film, LDH, liver function, and imaging (ultrasound ± CT).
- Consider bone marrow biopsy in cases of unexplained cytopenias or suspected haematological malignancy.
- Post-splenectomy patients require lifelong vaccinations (pneumococcal, meningococcal, Haemophilus influenzae type b) and may need prophylactic antibiotics.
- Aboriginal and Torres Strait Islander populations have a higher burden of infections and conditions leading to splenomegaly, requiring culturally safe, community-based care.
Introduction & Australian Epidemiology
Splenomegaly is a clinical sign, not a disease, indicating an underlying pathological process. It arises from numerous causes including haematological malignancies, portal hypertension, infections, and storage disorders, requiring systematic evaluation. In Australia, the epidemiology of splenomegaly reflects the diverse population, with common causes including chronic liver disease, haematological malignancies, and infections such as Ross River virus and Barmah Forest virus. The prevalence of specific conditions varies, with haematological malignancies being a significant consideration in older adults and infections more common across all age groups.
The spleen acts as a filter for blood, participating in immune surveillance and haematopoiesis. Its enlargement can lead to hypersplenism, causing cytopenias, and increases the risk of traumatic rupture. A structured approach to investigation is crucial to identify the underlying aetiology and guide management.
Causes & Classification
Causes of splenomegaly are broadly classified into five categories:
| Category | Examples |
|---|---|
| Congestive / Portal Hypertension | Cirrhosis (alcohol, viral hepatitis), Budd-Chiari syndrome, portal vein thrombosis, hepatic schistosomiasis |
| Infections | Acute: Infectious mononucleosis (EBV), cytomegalovirus, HIV, viral hepatitis, Ross River virus, Barmah Forest virus. Chronic: Tuberculosis, malaria, brucellosis, infective endocarditis, visceral leishmaniasis. |
| Haematological | Malignant: Myeloproliferative neoplasms (e.g., primary myelofibrosis, CML), lymphoproliferative disorders (e.g., CLL, lymphoma), hairy cell leukaemia. Benign: Haemolytic anaemias (e.g., hereditary spherocytosis, thalassaemia major), megaloblastic anaemia. |
| Inflammatory / Autoimmune | Rheumatoid arthritis (Felty syndrome), systemic lupus erythematosus, sarcoidosis |
| Infiltrative / Storage | Gaucher disease, Niemann-Pick disease, amyloidosis, metastatic cancer (rare) |
Clinical Pearl: Massive splenomegaly (weight >1000g or extending to the right iliac fossa) is highly suggestive of chronic myeloid leukaemia (CML), primary myelofibrosis, hairy cell leukaemia, or chronic malaria (e.g., hyperreactive malarial splenomegaly).
Clinical Features & Examination
The spleen is normally not palpable. Palpability suggests enlargement, but a palpable spleen is not always pathological (e.g., in thin individuals). Symptoms may be absent or include early satiety, left upper quadrant pain or fullness, and referred pain to the left shoulder (Kehr's sign).
Physical Examination Technique
- Position: Patient supine, with knees flexed to relax abdominal muscles. Examine from the right side.
- Palpation: Start in the right iliac fossa. Ask the patient to take a deep breath. Feel for the splenic edge moving towards the fingertips on inspiration. A palpable spleen is at least 1.5-2x enlarged.
- Percussion: Traube's space (left 6th-10th ribs, anterior axillary line) may be dull. Castle's method: percuss from the left costal margin towards the umbilicus; loss of tympany may indicate splenomegaly.
Clinical examination has limited sensitivity (60-70%) and specificity. Ultrasound is required for confirmation.
Investigations (FBC, Film, Imaging)
Investigation is tailored to the clinical context. A stepwise approach is recommended.
Initial Investigations
Essential
Complete Blood Count (CBC) with Differential
MBS Item 65070. Look for cytopenias (hypersplenism), leukocytosis, atypical cells, or polycythaemia.
Essential
Peripheral Blood Film
MBS Item 65080. Essential for identifying target cells, spherocytes, teardrop cells, leukoerythroblastic picture, or parasites.
Essential
Liver Function Tests (LFTs)
To assess for chronic liver disease and portal hypertension.
Available
Lactate Dehydrogenase (LDH)
Marker of haemolysis and cell turnover.
Available
Ultrasound Abdomen
First-line imaging. Measures splenic length (normal <12 cm). Assesses portal vein patency and liver morphology.
Further Investigations (Based on Clinical Suspicion)
Consider
CT Abdomen/Pelvis with Contrast
For detailed anatomical assessment, detecting lymphadenopathy, or evaluating for splenic infarction.
Specialist
Bone Marrow Aspiration & Biopsy
For unexplained cytopenias, suspected haematological malignancy, or storage diseases.
Specialist
Flow Cytometry, Cytogenetics, Molecular Tests
For suspected lymphoproliferative or myeloproliferative disorders.
Consider
Liver Elastography (FibroScan®)
Non-invasive assessment of liver fibrosis if portal hypertension is suspected.
MBS Note: Many specialist haematology tests (e.g., bone marrow biopsy) require referral to a specialist or public hospital haematology department. Bulk-billing arrangements may vary.
Management & Splenectomy Indications
Management is entirely directed at the underlying cause. Symptomatic treatment is limited.
Medical Management
- Treat the underlying cause: Antibiotics for infections, disease-modifying therapy for autoimmune conditions, targeted therapy for haematological malignancies.
- Manage hypersplenism: If cytopenias are severe and symptomatic, treat the primary disease. Splenectomy is a last resort.
Splenectomy: Indications and Considerations
Splenectomy (laparoscopic preferred) is considered for:
- Diagnostic: Undiagnosed splenomegaly after exhaustive non-invasive workup and bone marrow biopsy.
- Therapeutic - Hypersplenism: Severe, symptomatic cytopenias (e.g., transfusion-dependent anaemia, life-threatening thrombocytopenia) unresponsive to medical therapy.
- Therapeutic - Specific Diseases:
- Hereditary spherocytosis (with significant anaemia or gallstones).
- Primary myelofibrosis (with symptomatic massive splenomegaly).
- Hairy cell leukaemia (if refractory to medical therapy).
- Immune thrombocytopenia (ITP) (refractory, chronic).
- Massive Splenomegaly: For symptom relief (pain, early satiety, mechanical compression).
- Splenic Rupture: Emergency splenectomy for traumatic rupture.
Critical Pre-Splenectomy Care: All patients must receive vaccinations at least 2 weeks prior to elective splenectomy: 23-valent pneumococcal (Pneumovax® 23), meningococcal B (Bexsero®) and ACWY (Nimenrix®), and Haemophilus influenzae type b (Hib). Post-splenectomy, lifelong daily prophylactic phenoxymethylpenicillin (Penicillin V) 250 mg BD is recommended by some guidelines, though practice varies. Educate on infection risk and fever management plan.
Special Populations
Paediatrics
A common cause is infectious mononucleosis (EBV). Haemolytic anaemias and storage disorders also present in childhood.
Ultrasound is preferred due to lack of radiation.
Splenectomy is avoided in children <5 years due to high risk of overwhelming post-splenectomy infection (OPSI).
Pregnancy
Splenomegaly may be noted in pregnancy due to increased blood volume.
Consider gestational conditions (e.g., HELLP syndrome) and haematological changes.
MRI is the preferred second-line imaging modality in pregnancy if ultrasound is inconclusive.
Elderly
Higher prevalence of myeloproliferative and lymphoproliferative disorders.
May have concurrent chronic liver disease or heart failure.
Assess fitness for splenectomy carefully due to comorbidities.
Immunocompromised
At risk for atypical and opportunistic infections (e.g., Mycobacterium avium complex, fungal infections).
HIV-associated splenomegaly is common and may be multifactorial.
Consider lymphoma or Kaposi sarcoma in advanced HIV.
Aboriginal and Torres Strait Islander Health Considerations
Considerations for Aboriginal and Torres Strait Islander Peoples
The burden of conditions causing splenomegaly is higher among Aboriginal and Torres Strait Islander peoples, particularly in remote communities. A culturally safe, holistic, and community-embedded approach is essential.
Action: Engage with local ACCHOs and Aboriginal Liaison Officers. Use the NSQHS Standards Partnering with Consumers framework. Ensure communication is clear, respectful, and involves family as appropriate.
📚 References
- 1. Pozo AL, Godfrey EM, Bowles KM. Splenomegaly: investigation, diagnosis and management. Blood Rev. 2009;23(3):105-111.
- 2. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011;378(9785):86-97.
- 3. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. East Melbourne: RACGP; 2016.
- 4. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework. Canberra: AIHW; 2023.
- 5. Australasian Society for Infectious Diseases (ASID). Guidelines for the prevention of infection in patients with an absent or dysfunctional spleen. Sydney: ASID; 2019.
- 6. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(5):827-847.
- 7. Bloodsafe. Pre-splenectomy vaccination guide. [Internet]. Available from: https://www.bloodsafe.com.au
- 8. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2022.
- 9. Lane S, et al. The post-splenectomy state. Aust Prescr. 2021;44(1):4-10.
- 10. National Health and Medical Research Council (NHMRC). Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC; 2020. [For cirrhosis prevention context].